Status:

TERMINATED

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Lead Sponsor:

Novartis

Conditions:

Constipation

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.

Eligibility Criteria

Inclusion

  • Male and female outpatients 18 years of age or older.
  • Patients with chronic non-cancer pain that necessitates the use of non-injectable opioid analgesics. The equivalent dose of 300 mg morphine per day is the maximum opioid analgesic dose allowed. In general, patients should be using opioids on a daily basis.
  • Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.
  • Constipation, according to the investigator's clinical judgment, that is resulting from opioid use for non-cancer chronic pain. Opioid-induced constipation (OIC) is defined as follows:
  • less than 3 spontaneous bowel movements per week and at least one of the following on at least 25% of occasions:
  • hard or very hard stools
  • sensation of incomplete evacuation
  • straining while having a bowel movement

Exclusion

  • Patients who are receiving opioids for abdominal pain or connective tissue disorders.
  • Planned discontinuation or an increase or decrease by more than 30% of the current opioid dose
  • Patients who underwent major surgery within 3 months prior to screening.
  • Patients with a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
  • Patients with a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.
  • Other protocol-defined inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

July 1 2006

Trial Type :

INTERVENTIONAL

End Date :

April 1 2007

Estimated Enrollment :

670 Patients enrolled

Trial Details

Trial ID

NCT00365820

Start Date

July 1 2006

End Date

April 1 2007

Last Update

April 20 2012

Active Locations (59)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 15 (59 locations)

1

Investigative Site

Mobile, Alabama, United States, 36608

2

Investigative Site

Phoenix, Arizona, United States, 85029

3

Investigative Site

Phoenix, Arizona, United States, 85050

4

Investigative Site

Tucson, Arizona, United States, 85712